Cargando…
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922113/ https://www.ncbi.nlm.nih.gov/pubmed/33671367 http://dx.doi.org/10.3390/cells10020422 |
_version_ | 1783658615180099584 |
---|---|
author | De Logu, Francesco Galli, Francesca Nassini, Romina Ugolini, Filippo Simi, Sara Cossa, Mara Miracco, Clelia Gianatti, Andrea De Giorgi, Vincenzo Rulli, Eliana Cossu, Antonio Massi, Daniela Mandalà, Mario |
author_facet | De Logu, Francesco Galli, Francesca Nassini, Romina Ugolini, Filippo Simi, Sara Cossa, Mara Miracco, Clelia Gianatti, Andrea De Giorgi, Vincenzo Rulli, Eliana Cossu, Antonio Massi, Daniela Mandalà, Mario |
author_sort | De Logu, Francesco |
collection | PubMed |
description | Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. Materials and Methods: digital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM ≥ 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort. Results: in the training cohort, 100 Stage II–III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4(+) intratumoral T-cells (aHR [100 cell/mm(2) increase] 0.98, 95%CI 0.95–1.00, p = 0.041) and CD163(+) inner peritumoral (aHR [high vs. low] 0.56, 95%CI 0.32–0.99, p = 0.047). A statistically significant longer DFS (aHR [high-high vs. low-low] 0.52, 95%CI 0.28–0.99, p = 0.047) and overall survival (OS) (aHR [high-high vs. low-low] 0.39, 95%CI 0.18–0.85, p = 0.018) was found in patients with a high density of both intratumoral CD8(+) T-cells and CD68(+) macrophages as compared to those with low density of both intratumoral CD8(+) T-cells and CD68(+) macrophages. Consistently, in the validation cohort, patients with high density of both intratumoral CD8(+) and CD3(+) T-cells were associated to a statistically better DFS (aHR[high-high vs. low-low] 0.24, 95%CI 0.10–0.56, p < 0.001) and those with high density of both intratumoral CD8(+) and CD68(+) were associated to a statistically longer OS (aHR[high-high vs. low-low] 0.28, 95%CI 0.09–0.86, p = 0.025). Conclusion: our findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II–III melanoma patients. |
format | Online Article Text |
id | pubmed-7922113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79221132021-03-03 Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients De Logu, Francesco Galli, Francesca Nassini, Romina Ugolini, Filippo Simi, Sara Cossa, Mara Miracco, Clelia Gianatti, Andrea De Giorgi, Vincenzo Rulli, Eliana Cossu, Antonio Massi, Daniela Mandalà, Mario Cells Article Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. Materials and Methods: digital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM ≥ 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort. Results: in the training cohort, 100 Stage II–III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4(+) intratumoral T-cells (aHR [100 cell/mm(2) increase] 0.98, 95%CI 0.95–1.00, p = 0.041) and CD163(+) inner peritumoral (aHR [high vs. low] 0.56, 95%CI 0.32–0.99, p = 0.047). A statistically significant longer DFS (aHR [high-high vs. low-low] 0.52, 95%CI 0.28–0.99, p = 0.047) and overall survival (OS) (aHR [high-high vs. low-low] 0.39, 95%CI 0.18–0.85, p = 0.018) was found in patients with a high density of both intratumoral CD8(+) T-cells and CD68(+) macrophages as compared to those with low density of both intratumoral CD8(+) T-cells and CD68(+) macrophages. Consistently, in the validation cohort, patients with high density of both intratumoral CD8(+) and CD3(+) T-cells were associated to a statistically better DFS (aHR[high-high vs. low-low] 0.24, 95%CI 0.10–0.56, p < 0.001) and those with high density of both intratumoral CD8(+) and CD68(+) were associated to a statistically longer OS (aHR[high-high vs. low-low] 0.28, 95%CI 0.09–0.86, p = 0.025). Conclusion: our findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II–III melanoma patients. MDPI 2021-02-17 /pmc/articles/PMC7922113/ /pubmed/33671367 http://dx.doi.org/10.3390/cells10020422 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Logu, Francesco Galli, Francesca Nassini, Romina Ugolini, Filippo Simi, Sara Cossa, Mara Miracco, Clelia Gianatti, Andrea De Giorgi, Vincenzo Rulli, Eliana Cossu, Antonio Massi, Daniela Mandalà, Mario Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title | Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title_full | Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title_fullStr | Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title_full_unstemmed | Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title_short | Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients |
title_sort | digital immunophenotyping predicts disease free and overall survival in early stage melanoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922113/ https://www.ncbi.nlm.nih.gov/pubmed/33671367 http://dx.doi.org/10.3390/cells10020422 |
work_keys_str_mv | AT delogufrancesco digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT gallifrancesca digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT nassiniromina digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT ugolinifilippo digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT simisara digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT cossamara digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT miraccoclelia digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT gianattiandrea digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT degiorgivincenzo digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT rullieliana digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT cossuantonio digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT massidaniela digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients AT mandalamario digitalimmunophenotypingpredictsdiseasefreeandoverallsurvivalinearlystagemelanomapatients |